5'-Nucleotidase, Cytosolic II (NT5C2) antibody

Antigen: 5'-Nucleotidase, Cytosolic II (NT5C2)

Synonyms: GMP, NT5B, PNT5, cN-II, Gmp, CnII, Nt5b, Pnt5, 2010002I23Rik, NT5C2, wu:fc36f11, wu:fc45b10, MGC84715, nt5c2, MGC108319, DKFZp459F2431

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Application: Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Immunoprecipitation (IP), Western Blotting (WB)

Catalog no.: ABIN492874

Additional Information

Characteristics: Synonyms: NT5B, NT5CP, PNT5, Cytosolic purine 5'-nucleotidase

Alternative name: NT5C2

Gene ID: 22978

Swiss-Prot: P49902

Immunogen: Synthetic peptides corresponding to cNII sequence

Cross-Reactivity: Human, Mouse (Murine), Rat (Rattus)

Description: Various cytotoxic nucleoside analogs (NA) have been employed in the treatment ofhematologic malignancies. These NA include pyrimidine analog cytosine arabinoside(ara-c) and purine analogs, cladribine and fludarabine. These NA become therapeuticallyeffective only after phosporylation to the triphosphate level. The 5’-nucleotidases (5’-NTs)dephosphorylate the monophosphate form of NA and, therefore, may affect thepharmacological activity of these antimetabolites. Several 5’-NTs attached to membranesor present in the cytosol or in mitochondri. There are two cytosolic cyclic 5’nucleotidasesare cN-II and dNT-1 and one mitochondrial (dNT-2) nucleotidase known to be present in thecells. cN-I plays a significant role in AMP breakdown to adenosine whereas cN-II breaksdown IMP to inosine and GMP to guanosine. The primary sequence of CNI is unrelated toCNII or ecto-5’nucleotisdase (e-N). The tissue distribution of cNI cNII is different, cNI isfound only in vertebrate heart where as cNII is expressed in heart, brain and muscle. Sequence alignments of cytosolic 5’-nucleotidase, along with other nucleotidases, suggestthat cytosolic 5’nucleotidase belong to a large superfamily of hydrolases with differentsubstrate specificities and functional roles. Overproduction of cN-II could lead toresistance against anti-cancer drugs based on purine analogs. cN-II is Mg2+-dependent,regulated and stabilized by several factors such as allosteric effectors ATP and 2,3-DPG,although these are not directly involved in the reaction stoichiometry (2). IMP and GMP and its derivatives specific cytosolic 5’-nucleotidase (cNII) acts through theformation of a phosphoenzyme intermediate. Phosphate either released leading to5’-mononucleotide hydrolysis or transferred to an appropriate nucleoside acceptor, givingrise to a mononucleotide interconversion. Chemical reagents specifically modifyingaspartate and glutamate residues inhibit the enzyme, and this inhibition is partiallyprevented by cN-II substrates and physiological inhibitors (3). Site-directed mutagenesisexperiments confirmed the essential role of Asp-52 in the catalytic machinery of theenzyme and suggested also that Asp-54 assists in the formation of the acyl phosphatespecies. There exist a putative phsohorylation site on the cNII near C-termianl end of theprotein. FabGennix Int. Inc. , has also produced a phsopho-specific antibody tophospho-serine residue at this site (phosphorylation site: ILFRSG(Sp)RQTLES). The CNIIexist as monomer (40 kDa) and multimeric forms in various tissues.

Specificity: This strongly labelc a 40-42 kDa cNII and its multimerric forms in positive control. Species Reactivity: Tested: Human, mouse, rat

Application Details

Application Notes: Immunohistochemistry on frozen sections. ELISA. Western blot: > 1: 500. IMM and i. p pull-down assays: > 1: 200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Concentration: 0.75 - 0.95 mg/ml (lot specific)

Purification: Aff - Purified

Buffer: Stabilization buffer

Storage: Store (in aliquots) at -20 °C. Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Research Area: Chromatin and Nuclear Signaling, DNA/RNA

Restrictions: For Research Use only